ALEC: the cashflow

MyFinsight

For the quarter ending 2025-09-30, ALEC had $31,732K increase in cash & cash equivalents over the period. -$32,522K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-34,667	-70,995
Depreciation and amortization	1,237	3,313
Stock-based compensation	6,402	15,413
Amortization of premiums and accretion of discounts on marketable securities	1,548	3,785
Amortization of right-of-use assets	1,095	1,757
Amortization of debt discount and debt issuance costs	75	140
Impairment of right-of-use assets and leasehold improvements	0	1,151
Prepaid expenses and other current assets	-2,621	478
Other assets	-23	-50
Accounts payable	2,540	2
Accrued liabilities and accrued clinical supply costs	2,514	-16,507
Payable to collaboration partner	4,181	693
Deferred revenue	-3,260	-11,548
Refund liability to collaboration partner	12,041	26,063
Lease liabilities	-1,683	-3,182
Other long-term liabilities	0	210
Net cash used in operating activities	-32,511	-109,829
Purchase of property and equipment	11	30
Purchase of marketable securities	58,952	131,879
Maturities of marketable securities	108,505	250,385
Sale of marketable secuirities	0	2,981
Net cash provided by investing activities	49,542	121,457
Proceeds from issuance of common stock, net of issuance costs	14,701	-
Purchase of common stock under employee stock purchase plan	0	122
Proceeds from issuance of common stock upon public offering, net of issuance costs	-	0
Net cash provided by financing activities	14,701	122
Net increase (decrease) in cash, cash equivalents, and restricted cash	31,732	11,750
Cash and cash equivalents at beginning of period	34,867	-
Cash and cash equivalents at end of period	78,349	-

Unit: Thousand (K) dollars